284 related articles for article (PubMed ID: 25156329)
1. Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment.
Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
J Int Neuropsychol Soc; 2014 Sep; 20(8):836-47. PubMed ID: 25156329
[TBL] [Abstract][Full Text] [Related]
2. Increasing Inaccuracy of Self-Reported Subjective Cognitive Complaints Over 24 Months in Empirically Derived Subtypes of Mild Cognitive Impairment.
Edmonds EC; Weigand AJ; Thomas KR; Eppig J; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW
J Int Neuropsychol Soc; 2018 Sep; 24(8):842-853. PubMed ID: 30278855
[TBL] [Abstract][Full Text] [Related]
3. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates.
Bondi MW; Edmonds EC; Jak AJ; Clark LR; Delano-Wood L; McDonald CR; Nation DA; Libon DJ; Au R; Galasko D; Salmon DP
J Alzheimers Dis; 2014; 42(1):275-89. PubMed ID: 24844687
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors.
Edmonds EC; Delano-Wood L; Clark LR; Jak AJ; Nation DA; McDonald CR; Libon DJ; Au R; Galasko D; Salmon DP; Bondi MW;
Alzheimers Dement; 2015 Apr; 11(4):415-24. PubMed ID: 24857234
[TBL] [Abstract][Full Text] [Related]
5. Statistically Derived Subtypes and Associations with Cerebrospinal Fluid and Genetic Biomarkers in Mild Cognitive Impairment: A Latent Profile Analysis.
Eppig JS; Edmonds EC; Campbell L; Sanderson-Cimino M; Delano-Wood L; Bondi MW;
J Int Neuropsychol Soc; 2017 Aug; 23(7):564-576. PubMed ID: 28578726
[TBL] [Abstract][Full Text] [Related]
6. In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion.
Hessen E; Kirsebom BE; Eriksson CM; Eliassen CF; Nakling AE; Bråthen G; Waterloo KK; Aarsland D; Fladby T
J Alzheimers Dis; 2019; 67(2):715-723. PubMed ID: 30614807
[TBL] [Abstract][Full Text] [Related]
7. Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany.
Bartels C; Kögel A; Schweda M; Wiltfang J; Pentzek M; Schicktanz S; Schneider A
J Alzheimers Dis; 2020; 78(3):1137-1148. PubMed ID: 33104034
[TBL] [Abstract][Full Text] [Related]
8. Subjective cognitive complaints are important in PD-MCI criteria: Associations with CSF markers and cognitive decline.
Jones JD; Rivas R; Luna K; Ryczek CA; Thomas KR
Parkinsonism Relat Disord; 2023 Jan; 106():105221. PubMed ID: 36442366
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease.
Okonkwo OC; Alosco ML; Griffith HR; Mielke MM; Shaw LM; Trojanowski JQ; Tremont G;
Arch Neurol; 2010 Jun; 67(6):688-96. PubMed ID: 20558388
[TBL] [Abstract][Full Text] [Related]
10. Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.
Gleason CE; Norton D; Anderson ED; Wahoske M; Washington DT; Umucu E; Koscik RL; Dowling NM; Johnson SC; Carlsson CM; Asthana S;
J Alzheimers Dis; 2018; 61(1):79-89. PubMed ID: 29125485
[TBL] [Abstract][Full Text] [Related]
11. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
[TBL] [Abstract][Full Text] [Related]
12. Self- and informant-reported cognitive functioning and awareness in subjective cognitive decline, mild cognitive impairment, and very mild Alzheimer disease.
Ryu SY; Kim A; Kim S; Park KW; Park KH; Youn YC; Lee DW; Lee JY; Lee JH; Jeong JH; Choi SH; Han HJ; Kim S; Na S; Park M; Yim HW; Yang DW
Int J Geriatr Psychiatry; 2020 Jan; 35(1):91-98. PubMed ID: 31650618
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
Wolfsgruber S; Polcher A; Koppara A; Kleineidam L; Frölich L; Peters O; Hüll M; Rüther E; Wiltfang J; Maier W; Kornhuber J; Lewczuk P; Jessen F; Wagner M
J Alzheimers Dis; 2017; 58(3):939-950. PubMed ID: 28527210
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
[TBL] [Abstract][Full Text] [Related]
15. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
[TBL] [Abstract][Full Text] [Related]
16. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
17. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
[TBL] [Abstract][Full Text] [Related]
18. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
19. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
Podhorna J; Krahnke T; Shear M; Harrison JE;
Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]